221 related articles for article (PubMed ID: 22355050)
1. Targeting adjuvant chemotherapy: a good idea that needs to be proven!
Hayes DF
J Clin Oncol; 2012 Apr; 30(12):1264-7. PubMed ID: 22355050
[No Abstract] [Full Text] [Related]
2. Is adjuvant chemotherapy useful for women with luminal a breast cancer?
Coates AS; Colleoni M; Goldhirsch A
J Clin Oncol; 2012 Apr; 30(12):1260-3. PubMed ID: 22355052
[No Abstract] [Full Text] [Related]
3. Patients with anti-HER2 responsive disease: definition and adjuvant therapies.
Burstein HJ
Breast; 2011 Oct; 20 Suppl 3():S132-4. PubMed ID: 22015280
[TBL] [Abstract][Full Text] [Related]
4. To switch or not to switch: should the study of tamoxifen and raloxifene (STAR) trial alter our decision?
Wang PH; Chao HT
Taiwan J Obstet Gynecol; 2008 Sep; 47(3):372-4. PubMed ID: 18936014
[No Abstract] [Full Text] [Related]
5. Surgery following neoadjuvant therapy in patients with HER2-positive locally advanced or inflammatory breast cancer participating in the NeOAdjuvant Herceptin (NOAH) study.
Semiglazov V; Eiermann W; Zambetti M; Manikhas A; Bozhok A; Lluch A; Tjulandin S; Sabadell MD; Caballero A; Valagussa P; Baselga J; Gianni L
Eur J Surg Oncol; 2011 Oct; 37(10):856-63. PubMed ID: 21843921
[TBL] [Abstract][Full Text] [Related]
6. The use of aromatase inhibitors in postmenopausal women with hormone receptor positive breast cancer.
Benson JR
J Clin Oncol; 2005 Sep; 23(27):6807-9. PubMed ID: 16170197
[No Abstract] [Full Text] [Related]
7. Is there a case for anti-HER2 therapy without chemotherapy in early breast cancer?
Constantinidou A; Smith I
Breast; 2011 Oct; 20 Suppl 3():S158-61. PubMed ID: 22015286
[TBL] [Abstract][Full Text] [Related]
8. [DCIS and HER2/neu].
Tulusan AH
Onkologie; 2002 Dec; 25 Suppl 5():11-2; discussion 13. PubMed ID: 23573612
[No Abstract] [Full Text] [Related]
9. Adjuvant taxanes in the treatment of breast cancer: no longer at the tip of the iceberg.
Dang C; Hudis C
Clin Breast Cancer; 2006 Apr; 7(1):51-8. PubMed ID: 16764744
[TBL] [Abstract][Full Text] [Related]
10. The continued evidence from overviews: what is the clinical utility?
Turner N; Biganzoli L; Malorni L; Migliaccio I; Moretti E; Pestrin M; Sanna G; Siclari O; Di Leo A
Breast; 2013 Aug; 22 Suppl 2():S8-11. PubMed ID: 24074798
[TBL] [Abstract][Full Text] [Related]
11. Recent advances in the hormonal treatment of breast cancer.
Boughey JC; Buzdar AU; Hunt KK
Curr Probl Surg; 2008 Jan; 45(1):13-55. PubMed ID: 18206436
[No Abstract] [Full Text] [Related]
12. Early response to neo-adjuvant chemotherapy in carcinoma of the breast predicts both successful breast-conserving surgery and decreased risk of ipsilateral breast tumor recurrence.
Ishitobi M; Komoike Y; Motomura K; Koyama H; Inaji H
Breast J; 2010; 16(1):9-13. PubMed ID: 19929889
[TBL] [Abstract][Full Text] [Related]
13. Neoadjuvant trastuzumab for breast cancer. Better to stick with proven treatments.
Prescrire Int; 2013 Feb; 22(135):39. PubMed ID: 23444499
[TBL] [Abstract][Full Text] [Related]
14. Adjuvant hormonal therapy in perimenopausal patients.
Pinto Marín A; Ballesteros García AI; Izarzugaza Perón Y; Mansó Sánchez L; López-Tarruella Cobo S; Zamora Auñón P
Adv Ther; 2011 Sep; 28 Suppl 6():39-49. PubMed ID: 21922394
[TBL] [Abstract][Full Text] [Related]
15. Small tumor size and node-negative HER2-positive breast cancer: a step forward for a better treatment?
Crivellari D; Molino A
J Clin Oncol; 2010 Jun; 28(16):e257; author reply e258-9. PubMed ID: 20368536
[No Abstract] [Full Text] [Related]
16. [Sequencing of adjuvant treatment after surgery for invasive breast cancer].
Petit T; Claude L; Carrie C
Cancer Radiother; 2004 Feb; 8(1):54-8. PubMed ID: 15093202
[TBL] [Abstract][Full Text] [Related]
17. Patients with triple negative breast cancer: is there an optimal adjuvant treatment?
Burstein HJ
Breast; 2013 Aug; 22 Suppl 2():S147-8. PubMed ID: 24074776
[No Abstract] [Full Text] [Related]
18. [The effectiveness of adjuvant systemic therapy in organ-preserving therapy of breast cancer].
Semiglazov VF; Kanaev SV; Bugrova IL; Chagunava OL
Vopr Onkol; 1998; 44(4):408-13. PubMed ID: 9807203
[TBL] [Abstract][Full Text] [Related]
19. Disease-free survival advantage of weekly epirubicin plus tamoxifen versus tamoxifen alone as adjuvant treatment of operable, node-positive, elderly breast cancer patients: 6-year follow-up results of the French adjuvant study group 08 trial.
Fargeot P; Bonneterre J; Roché H; Lortholary A; Campone M; Van Praagh I; Monnier A; Namer M; Schraub S; Barats JC; Guastalla JP; Goudier MJ; Chapelle-Marcillac I
J Clin Oncol; 2004 Dec; 22(23):4622-30. PubMed ID: 15505276
[TBL] [Abstract][Full Text] [Related]
20. Weekly epirubicin plus tamoxifen versus tamoxifen alone as adjuvant treatment of operable, node-positive, elderly breast cancer patients.
Alliot C
J Clin Oncol; 2005 Jun; 23(18):4237-8; author reply 4238-9. PubMed ID: 15961776
[No Abstract] [Full Text] [Related]
[Next] [New Search]
